Related Experiment Video
Updated: Oct 22, 2025
Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity
Published on: May 1, 2018
Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy
Soo Ghee Yeoh1, Jia Siang Sum1, Jing Yi Lai1
1Institute for Research in Molecular Medicine, Universiti Sains Malaysia, 11800, Penang, Malaysia.
Insights
This review explores using phage display to create monoclonal antibodies for managing cholesterol levels, a key factor in cardiovascular disease (CVD) prevention and treatment.
Area of Science:
- Immunology
- Cardiology
- Biotechnology
Background:
- Cardiovascular disease (CVD) is a major global cause of mortality, encompassing conditions like heart attack and stroke.
- The "cholesterol hypothesis" links plasma cholesterol levels to CVD risk.
- Current treatments primarily involve statins, but biological interventions are being explored.
Purpose of the Study:
- To review the potential of phage display technology for developing therapeutic monoclonal antibodies.
- To identify potential target antigens for serum cholesterol management in cardiovascular disease.
Main Methods:
- Phage display technology for antibody development.
- Literature review of existing research on monoclonal antibodies and cholesterol management.
Main Results:
- Phage display is a proven method for generating therapeutic antibodies.
- Monoclonal antibodies offer a potential alternative or adjunct to statins for cholesterol regulation.
- Specific target antigens for cholesterol management via immunotherapy require further investigation.
Conclusions:
- Phage display is a viable platform for creating antibodies targeting cardiovascular disease.
- Expanding monoclonal antibody applications to CVD could offer new therapeutic avenues.
- Further research is needed to identify and validate specific antigens for effective cholesterol management.
Abstract:
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. CVD includes coronary artery diseases such as angina, myocardial infarction, and stroke. "Lipid hypothesis" which is also known as the cholesterol hypothesis proposes the linkage of plasma cholesterol level with the risk of developing CVD. Conventional management involves the use of statins to reduce the serum cholesterol levels as means for CVD prevention or treatment. The regulation of serum cholesterol levels can potentially be regulated with biological interventions like monoclonal antibodies. Phage display is a powerful tool for the development of therapeutic antibodies with successes over the recent decade. Although mainly for oncology, the application of monoclonal antibodies as immunotherapeutic agents could potentially be expanded to CVD. This review focuses on the concept of phage display for antibody development and discusses the potential target antigens that could potentially be beneficial for serum cholesterol management.
